Could be? Idk, CTMX has beaten Earnings in the last four Quarts.will see today what big sharks decide for this stock and I will jump with them before the earning day, if they decide to short I will follow.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.17 USD
−569.00 K USD
101.21 M USD
76.79 M
About CytomX Therapeutics, Inc.
Sector
CEO
Sean A. McCarthy
Headquarters
South San Francisco
Website
Founded
2010
FIGI
BBG001J472L3
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.
CTMX Opportunity to hit 3.8 - 5.7 mark after the huge dropTheir recent study data ir.cytomx.com
Their ER PR ir.cytomx.com
Summary:
CytomX Therapeutics announces positive initial Phase 1a dose escalation data for monotherapy CX-904, a PROBODY® T-Cell Engager, demonstrating a favorable safety profile and encouraging efficacy in advanced pancreatic cancer
Stock Idea: $CTMX (8 Feb 2023)$CTMX
- Power-play setup on another Biotech stock
- Gapped up on strong volume on news of partnership with Moderna
- Been tightening up. Broke above downtrend resistance on Mon. Inside-day bar on Tue
CytomX Therapeutics Announces FDA Clearance of Investigational NCTMX: CytomX Therapeutics, Inc.
2022-01-19 08:00:00
CytomX Therapeutics Announces FDA Clearance of Investigational New Drug Application for CX-904 for the Treatment of Advanced Solid Tumors
Possible bullish runI am predicting a possible bullish run of over 300% given past historical data. When looking at the charts you’ll notice recurrent trends. First a price bearish downtrend that lasts a few months followed by a sudden 75% bullish run which is immediately followed by a sharp price dip of over 50%. Pric
BULLISHEngages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. Shareholders may be thrilled to learn that t
CYTOMX THERAPEUTICS INChigh probability next target 7.94
if the price strongly breaks the horizontal white line and closes above high probability next target 10.60
if you need an analysis do not hesitate to contact me.
don't forget to subscribe to receive updates if you find interesting what I do
CTMX trend reversal?The overall trend is down but recently strong bullish activity is happening. The share price shattered past the last stance of resistance around $11.50 and the last round of support is around $9.00. Can the bulls keep it up?
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of CTMX is 1.09 USD — it has increased by 9.00% in the past 24 hours. Watch CytomX Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange CytomX Therapeutics, Inc. stocks are traded under the ticker CTMX.
CTMX stock has risen by 5.83% compared to the previous week, the month change is a −4.39% fall, over the last year CytomX Therapeutics, Inc. has showed a −12.80% decrease.
We've gathered analysts' opinions on CytomX Therapeutics, Inc. future price: according to them, CTMX price has a max estimate of 8.00 USD and a min estimate of 3.25 USD. Watch CTMX chart and read a more detailed CytomX Therapeutics, Inc. stock forecast: see what analysts think of CytomX Therapeutics, Inc. and suggest that you do with its stocks.
CTMX reached its all-time high on Mar 8, 2018 with the price of 35.00 USD, and its all-time low was 0.99 USD and was reached on Oct 29, 2024. View more price dynamics on CTMX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
CTMX stock is 15.09% volatile and has beta coefficient of 0.93. Track CytomX Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is CytomX Therapeutics, Inc. there?
Today CytomX Therapeutics, Inc. has the market capitalization of 85.30 M, it has decreased by −8.15% over the last week.
Yes, you can track CytomX Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
CytomX Therapeutics, Inc. is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
CTMX earnings for the last quarter are 0.07 USD per share, whereas the estimation was −0.17 USD resulting in a 140.62% surprise. The estimated earnings for the next quarter are −0.22 USD per share. See more details about CytomX Therapeutics, Inc. earnings.
CytomX Therapeutics, Inc. revenue for the last quarter amounts to 33.43 M USD, despite the estimated figure of 17.10 M USD. In the next quarter, revenue is expected to reach 12.20 M USD.
CTMX net income for the last quarter is 5.74 M USD, while the quarter before that showed −6.53 M USD of net income which accounts for 187.79% change. Track more CytomX Therapeutics, Inc. financial stats to get the full picture.
No, CTMX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 10, 2024, the company has 122.00 employees. See our rating of the largest employees — is CytomX Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CytomX Therapeutics, Inc. EBITDA is 8.55 M USD, and current EBITDA margin is −4.26%. See more stats in CytomX Therapeutics, Inc. financial statements.
Like other stocks, CTMX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CytomX Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CytomX Therapeutics, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CytomX Therapeutics, Inc. stock shows the sell signal. See more of CytomX Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.